What We Do
At MBM, we are dedicated to becoming a world-class commercialization platform for precision healthcare products and services. In the world of life sciences today, there is no shortage of innovative discoveries. However, a significant gap exists between cutting edge discovery and turning these discoveries into a product that helps patients in need.
MBM’s sole purpose is to identify core technologies that will address unmet medical needs and translating these technologies into products that will help patients in China and around in the world. We are currently focused on novel cancer biomarker discovery and product development using MBMbio’s proprietary AI digital pathology and Red Blood Cell (RBC) liquid biopsy platforms.
We are working to develop the next wave of healthcare innovations.
Who Are We
We are leaders and experts in our field. Say hello to our team.
Latest Blog Posts
News and healthcare tips
Identification of Early Cancer through Peripheral Blood Mature Red Blood Cells! Chinese Scholars Reveal Cancer-Related Large DNA Fragments within Red Blood Cells for the First Time
Identification of Early Cancer through Peripheral Blood Mature Red Blood Cells! Chinese Scholars Reveal Cancer-Related Large DNA...
MBMbio announced residency at JLABS @ Shanghai
MBMbio announced residency at JLABS @ ShanghaiDecember 1, 2021Shanghai China, December 1, 2021 – MBMbio announced today that, effective...
Red Blood Cells Offer a Breakthrough in Liquid Biopsy Technology
The Often Neglected Red Blood Cell Offers a Breakthrough in Liquid Biopsy Technology for Early Stage Cancer Detection
Colorectal Cancer Recurrence Risk Assessment Marker Announcement
MBM’s “Colorectal Cancer Recurrence Risk Assessment Marker” announced at the National Colorectal Surgery Symposium
The revolution requires the right people.